MergerLinks Header Logo

Announced

Completed

BenevolentAI went public via a SPAC merger with Odyssey Acquisition in a $1.7bn deal.

Synopsis

BenevolentAI, a clinical-stage AI drug discovery company, went public via a SPAC merger with Odyssey Acquisition in a $1.7bn deal. The transaction includes a c.$152m PIPE from Temasek, AstraZeneca, Ally Bridge Group and Invus. "The combination with Odyssey will allow us to scale our vision and ambition of uniting purposeful technology and cutting-edge science to discover life-changing medicines," Joanna Shields, BenevolentAI CEO.

Show Details & Financials

Did you work on this deal?

Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.

Sort

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US